[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 685292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1063565, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 54000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 46, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 714747, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 59, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 47, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 40, "title": "SVP & Corporate Controller", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.13, "open": 1.13, "dayLow": 1.11, "dayHigh": 1.23, "regularMarketPreviousClose": 1.13, "regularMarketOpen": 1.13, "regularMarketDayLow": 1.11, "regularMarketDayHigh": 1.23, "payoutRatio": 0.0, "beta": 0.311, "forwardPE": -0.8615108, "volume": 1513646, "regularMarketVolume": 1513646, "averageVolume": 3120191, "averageVolume10days": 2569320, "averageDailyVolume10Day": 2569320, "bid": 1.16, "ask": 1.22, "bidSize": 2, "askSize": 2, "marketCap": 261930384, "fiftyTwoWeekLow": 0.86, "fiftyTwoWeekHigh": 3.78, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.3086, "twoHundredDayAverage": 1.96245, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 56045816, "profitMargins": 0.0, "floatShares": 157188709, "sharesOutstanding": 218731008, "sharesShort": 26041918, "sharesShortPriorMonth": 27361306, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.1191, "heldPercentInsiders": 0.17742, "heldPercentInstitutions": 0.80541, "shortRatio": 7.91, "shortPercentOfFloat": 0.1442, "impliedSharesOutstanding": 228408992, "bookValue": 1.763, "priceToBook": 0.6792399, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -252323008, "trailingEps": -1.22, "forwardEps": -1.39, "enterpriseToEbitda": -0.234, "52WeekChange": -0.47685188, "SandP52WeekChange": 0.12632763, "quoteType": "EQUITY", "currentPrice": 1.1975, "targetHighPrice": 14.0, "targetLowPrice": 2.5, "targetMeanPrice": 8.15, "targetMedianPrice": 8.5, "recommendationMean": 1.57143, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 280043008, "totalCashPerShare": 1.28, "ebitda": -239986000, "totalDebt": 88923000, "quickRatio": 9.405, "currentRatio": 9.712, "totalRevenue": 0, "debtToEquity": 23.073, "revenuePerShare": 0.0, "returnOnAssets": -0.28917998, "returnOnEquity": -0.59597, "grossProfits": -190240000, "freeCashflow": -96647504, "operatingCashflow": -197330000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "regularMarketTime": 1751393680, "cryptoTradeable": false, "fiftyTwoWeekChangePercent": -47.68519, "earningsTimestamp": 1747166704, "earningsTimestampStart": 1754424000, "earningsTimestampEnd": 1754942400, "earningsCallTimestampStart": 1747170000, "earningsCallTimestampEnd": 1747170000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.22, "epsForward": -1.39, "epsCurrentYear": -0.999, "priceEpsCurrentYear": -1.1986986, "fiftyDayAverageChange": -0.11109996, "fiftyDayAverageChangePercent": -0.084899865, "twoHundredDayAverageChange": -0.76495004, "twoHundredDayAverageChangePercent": -0.3897934, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "marketState": "REGULAR", "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 6.0133624, "regularMarketPrice": 1.1975, "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539264600000, "regularMarketChange": 0.067499995, "regularMarketDayRange": "1.11 - 1.23", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3120191, "fiftyTwoWeekLowChange": 0.33749998, "fiftyTwoWeekLowChangePercent": 0.39244184, "fiftyTwoWeekRange": "0.86 - 3.78", "fiftyTwoWeekHighChange": -2.5825, "fiftyTwoWeekHighChangePercent": -0.6832011, "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-01"}]